Incheon St.Mary's Hospital   Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Seoul Korea, Republic of (1955)

Organization Overview

First Clinical Trial
2016
NCT03243851
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Incheon St.Mary's Hospital

Active Ingredients

Drugs in Phase 4 Trials (2)

acetylsalicylic acid (aspirin) (1 trial)

dextrose (1 trial)

Drugs in Phase 3 Trials (2)

hepatitis a vaccine, inactivated (vaqta) (1 trial)

polyethylene glycol (1 trial)

Drugs in Phase 2 Trials (2)

metformin (glucophage) (1 trial)

temozolomide (temodar) (1 trial)

Drugs in Other Trials (2)

lansoprazole (prevacid) (1 trial)

tegoprazan (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Coronary Artery Disease (Phase 4)

Glioblastoma (Phase 2)

Hepatitis (Phase 3)

Hepatitis A (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 6
  • # of Trial APIs: 8